Adamas Pharmaceuticals discovers and develops therapies to improve the daily lives of people affected by chronic neurologic disorders. Symptoms associated with neurologic disorders are often treated sub-optimally due to tolerability issues, which may limit the amount of drug that is present when patients need relief.
We pioneered a platform to develop medicines for chronic neurologic disorders, which is built up on our understanding of time-dependent biologic processes responsible for specific disease activities and drug response. We believe the lives of patients with neurologic disorders are improved when these factors operate in unison.
Our lead product candidate, ADS-5102, is a high-dose amantadine therapy, taken once daily at bedtime, in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. Over time, 90% of Parkinson’s disease patients on levodopa therapy will develop alternating periods of OFF time and levodopa-induced dyskinesia, as their disease progresses. Levodopa-induced dyskinesia is characterized by involuntary movements that are purposeless and unpredictable. A New Drug Application supporting ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA date of August 24, 2017. We are exploring other indications for ADS-5102 for further development.
We are also investigating ADS-4101, modified-release lacosamide capsules, for the treatment of partial onset seizures in patients with epilepsy. The active ingredient in ADS-4101 is lacosamide, an anti-epileptic, previously approved by the FDA and currently marketed by UCB as VIMPAT® (lacosamide).
Additionally, our licensed assets for the treatment of moderate to severe Alzheimer’s disease, Namenda XR® (memantine hydrochloride) extended-release capsules and Namzaric® (memantine hydrochloride extended-release and donepezil hydrochloride) capsules, are currently marketed by Allergan. We are eligible to receive royalties on sales of Namenda XR and Namzaric beginning in June of 2018 and May of 2020, respectively.
Namenda XR® and Namzaric® are registered trademarks of Merz Pharma GmbH & Co. KGaA. VIMPAT® is a registered trademark of UCB.